Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Shanghai Biolaxy Given SFDA OK for Oral Insulin IND

publication date: Nov 25, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shanghai Biolaxy received an SFDA approval of an investigational new drug application (IND) for its oral insulin product, Nodlin. Nodlin uses a patented bio-adhesive nano-particle oral delivery technology (NOD) to transport insulin through the stomach to the blood stream. No orally administered insulin drugs are approved currently. With a successful IND, Shanghai Biolaxy can begin clinical trials of the product. More details...

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...